MONTREAL, April 8 /PRNewswire-FirstCall/ - Haemacure Corporation
(TSX:HAE), a specialty bio-therapeutics company developing high-value human
therapeutic proteins for commercialization, will hold its Annual General
and Special Meeting of Shareholders on:
Date : Wednesday, April 9, 2008
Time: 4:00 p.m. ET
Place: The National Club
303 Bay Street
Mr. Joseph Galli, Chairman & CEO of Haemacure, will report on Haemacure's projects, recent developments and future outlook. Mr. Galli will also present an overview of the current clinical programs for Haemacure's proprietary fibrin sealant and hemostatic agent product candidates, construction of the Company's new manufacturing facility and growth potential.
For those who are unable to attend in person, Haemacure will simultaneously host a live webcast with slides of Mr. Galli's presentation at http://events.snwebcastcenter.com/haemacure/20080409/
About Haemacure Corporation
Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a human-derived fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is human thrombin, a component of its fibrin sealant, now in preclinical stage. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical haemostats, wound management, drug delivery, regenerative medicine, adhesion prevention and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these specialty proteins and enzymes through partnerships with pharmaceutical and biotechnology companies.
|SOURCE Haemacure Corporation|
Copyright©2008 PR Newswire.
All rights reserved